Sughayer Maher A, Al-Khawaja Maha M, Massarweh Suleiman, Al-Masri Mahmoud
Department of Pathology, King Hussein Cancer Center, Amman, 11941, Jordan.
Pathol Oncol Res. 2006;12(2):83-6. doi: 10.1007/BF02893449. Epub 2006 Jun 24.
The management and prognosis of breast cancer nowadays require the evaluation of Estrogen (ER), Progesterone Receptors (PR) and HER2/neu. Ethnic variation in the expression of these receptors is well documented. The aim of this study is to determine the prevalence of ER, PR and HER2/neu among Jordanian women with breast cancer of ductal and lobular types. A retrospective analysis was performed on 267 cases of breast cancer referred for treatment at King Hussein Cancer Center, Jordan between the period of June 2003 and June 2004. Standard immune stains were used for evaluation of hormone receptors and HER2/neu. In addition, evaluation of HER2/neu was done by FISH in selected cases. Of these 267 cases, 240 (89.9%) were ductal carcinomas of various histological grades, 122 (50.8%) of which were ER-positive, 138 (57.5%) PRpositive and 42 (17.5%) HER2/neu-positive. Twentytwo (8.2%) of all cases were lobular carcinomas, 15 (68%) of which were ER-positive, 20 (90.9%) PRpositive and 3 (13.6%) HER2/neu-positive. Five (1.9%) of the total cases were of mixed lobular and ductal types, 4 (80%) of which were ER-positive, 3 (60%) PR-positive and none were positive for HER2/neu. The prevalence of hormone receptor positivity in breast cancer of Jordanian women is lower than that of the western populations and close to other populations such as the Chinese and the minor ethnic groups of Northern America (African Americans).
如今,乳腺癌的管理和预后需要评估雌激素(ER)、孕激素受体(PR)和HER2/neu。这些受体表达的种族差异已有充分记录。本研究的目的是确定约旦导管型和小叶型乳腺癌女性中ER、PR和HER2/neu的患病率。对2003年6月至2004年6月期间在约旦侯赛因国王癌症中心接受治疗的267例乳腺癌病例进行了回顾性分析。使用标准免疫染色评估激素受体和HER2/neu。此外,对部分病例通过荧光原位杂交(FISH)评估HER2/neu。在这267例病例中,240例(89.9%)为不同组织学分级的导管癌,其中122例(50.8%)ER阳性,138例(57.5%)PR阳性,42例(17.5%)HER2/neu阳性。所有病例中有22例(8.2%)为小叶癌,其中15例(68%)ER阳性,20例(90.9%)PR阳性,3例(13.6%)HER2/neu阳性。总病例中有5例(1.9%)为小叶和导管混合型,其中4例(80%)ER阳性,3例(60%)PR阳性,HER2/neu均为阴性。约旦女性乳腺癌中激素受体阳性的患病率低于西方人群,与中国人群以及北美少数族裔(非裔美国人)等其他人群相近。